Project Grant R44AI197758
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Orlando, FL 32826, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded $922,799 to Seattle Children's Research Institute on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop bioengineered human brain microvessel platforms for modeling cerebral malaria disease mechanisms and developing adjunctive therapies. The research addresses the pathogenesis of cerebral malaria caused by Plasmodium falciparum, which leads to sequestration of infected red...
- The National Institute of Allergy and Infectious Diseases awarded Whitehead Institute for Biomedical Research $899,850 on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how apicomplexan parasites recognize and invade host cells. The funded research examines the molecular mechanisms by which parasites such as Toxoplasma and Plasmodium trigger rhoptry discharge—the secretion of proteins from specialized organelles upon contact with host...
- The National Institute of Allergy and Infectious Diseases awarded Hennepin Healthcare Research Institute $661,037 on May 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate an interleukin-15 (IL-15) cytokine-based therapy intended to enhance T and B cell immune responses to Plasmodium parasites and improve malaria vaccine efficacy. The research uses novel peptide-MHC class II and B cell tetramers in experimental Plasmodium infection and vaccination...
- The National Institute of Allergy and Infectious Diseases awarded Griffith University $1,098,414 on September 10, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to design, manufacture, and evaluate biopolymer particle-based multistage malaria vaccine candidates. The project, titled "Directed In Vivo Assembly of a Robust Biopolymer Particle-Based Multistage Malaria Vaccine," applies an innovative vaccine platform technology based on antigen-coated...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded Purdue University $239,023 on August 21, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop covalent phosphatidylinositol 4-kinase (PI4K) inhibitors targeting malaria parasites. The project executes hit-to-lead optimization of high-priority molecular scaffolds against Plasmodium species that inhibit...
- The National Institute of Allergy and Infectious Diseases awarded Iowa State University $578,956 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on the regulation of axoneme assembly during Plasmodium falciparum gametogenesis, a study aimed at advancing malaria vaccine development. The project, designated R01AI195769, runs through June 30, 2031, with work performed in Ames, Iowa. The research addresses the mechanisms of flagellar...
- The National Institute of Allergy and Infectious Diseases awarded the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. $223,728 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate Plasmodium falciparum gametocyte differentiation and adhesion mechanisms as part of Project Grant R21AI199783. The funded research addresses malaria transmission by examining the sexual stage parasites (gametocytes) responsible for...
- The National Institute of Allergy and Infectious Diseases awarded Case Western Reserve University $631,401 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop human monoclonal antibodies targeting Plasmodium vivax malaria. The research focuses on isolating and optimizing monoclonal antibodies (MAbs) that target the parasite's apical membrane protein 1 (AMA1) and circumsporozoite protein (CSP) to prevent and treat vivax malaria, which...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $788,453 under Project Grant R01AI198560 on September 2, 2026, to identify essential Plasmodium falciparum determinants of erythrocyte invasion using genome-scale functional genomic approaches. The research will employ a novel transposon-based strategy to map critical genes and molecular pathways underlying red blood cell invasion across multiple P. falciparum strains with distinct phenotypes in...
- The National Institute of Allergy and Infectious Diseases awarded $431,750 to the University of California Irvine on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Assistance Listing Project Grant R21AI199644). The award funds development and validation of a hydro-meteorological malaria model designed to improve forecasts of malaria risk in Africa and to inform tailored vector control strategies adapted to varying environmental and epidemiological...